Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results

All amounts are in U.S. dollars

QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) ("the Company"), a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

First Quarter 2010 Highlights

    - January 25, 2010: Updated results of a Phase 2 study related to the use
      of perifosine in the treatment of advanced metastatic colon cancer
      showing a statistically significant benefit in survival, including
      5 FU-refractory patients.

    - January 29, 2010: Publication in the February 2010 issue of the Journal
      of Clinical Cancer Research of positive Phase 2 results for perifosine
      as a single agent for the treatment of advanced Waldenstrom's

    - February 3, 2010: Special Protocol Assessment ("SPA") granted by the
      United States Food and Drug Administration ("FDA") for the Phase 3
      trial of perifosine in combination with capecitabine (Xeloda(R)) in
      refractory advanced colorectal cancer. The trial is to be conducted by
      Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), Aeterna
      Zentaris' partner and licensee for perifosine in North America.

    - March 1, 2010: Disclosure that the Committee for Orphan Medicinal
      Products of the European Medicines Agency ("EMA") had issued a positive
      opinion for orphan medicinal product designation for perifosine for the
      treatment of multiple myeloma.

Subsequent to Quarter-End

    - April 5, 2010: Perifosine receives FDA Fast Track Designation for the
      Phase 3 X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer
      Treatment) registration trial.

    - April 8, 2010: Initiation of a Phase 3 registration trial with
      perifosine in refractory advanced colorectal cancer by Keryx.

    - April 15, 2010: Positive Scientific Advice from the EMA for the Phase 3
      program with perifosine in multiple myeloma. Data from ongoing Phase 3
      study, sponsored by Keryx, can be used to register perifosine in
      multiple myeloma in Europe.

    - April 20, 2010: Presentations of preclinical data on Erk inhibitor,
      AEZS-131, and Erk/PI3K dual inhibitor, AEZS-132, as well as preclinical
      data from a study sponsored by the National Institutes of Health with
      perifosine in oncology at the American Association for Cancer Research
      Annual Meeting in Washington, D.C.

    - April 20, 2010: Completion of a $15.0 million registered direct
      offering with certain institutional investors.

    - April, 23, 2010: Company regained compliance with Nasdaq's minimum bid
      price listing requirement.

    - May 6, 2010: Company receives orphan-drug designation from the FDA for
      AEZS-108 in ovarian cancer.

    - May 12, 2010: FDA approves the Company's Investigational New Drug (IND)
      application for AEZS-108 in LHRH-receptor positive urothelial (bladder)

Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "This has been a very exciting quarter as we made great strides in the development of our lead oncology compound, perifosine, now in Phase 3 registration trials for multiple myeloma and refractory advanced colorectal cancer. Furthermore, the different designations recently granted by the FDA in both indications and the EMA's positive Scientific Advice for multiple myeloma, will accelerate as well as facilitate the future review and marketing authorization processes in North America and Europe."

Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris added, "With more than $40 million in cash, including proceeds from our recent $15 million registered direct offering and no debt, combined with our expected significantly reduced burn rate, we are in a solid financial position to execute our focused drug development and business strategy."


Revenues were $6.4 million for the three-month period ended March 31, 2010, compared to $6.1 million for the same period in 2009. The increase is mainly due to a comparative increase in sales of Cetrotide(R) to certain customers in the first quarter of 2010. This increase was partly offset by lower amortization of upfront license fee payments in 2010 related to our agreement with sanofi-aventis U.S. LLC ("sanofi-aventis"), which was entered into in March 2009, in connection with our now discontinued development program involving cetrorelix for the treatment of Benign Prostatic Hyperplasia ("BPH"), and subsequently terminated.

Research and development ("R&D") costs, net of tax credits and grants, were $5.7 million for the three-month period ended March 31, 2010, compared to $11.4 million for the same period in 2009. The comparative decrease in net R&D costs is almost entirely attributable to the winding down and termination of development activities related to cetrorelix in BPH, despite the presence in the first quarter of 2010 of residual expenditures associated with certain remaining contractual obligations.

Selling, general and administrative ("SG&A") expenses were $2.8 million for the three-month period ended March 31, 2010, compared to $3.6 million for the same period in 2009. This decrease is primarily related to lower comparative salary and benefit costs, lower legal expenses and other cost-saving measures.

Net loss was $5.9 million, or $0.09 per basic and diluted share, for the three-month period ended March 31, 2010, compared to $12.4 million, or $0.23 per basic and diluted share, for the same period in 2009. This decrease is mainly related to lower comparative net R&D costs, lower SG&A expenses and higher foreign exchange gains, partly offset by lower comparative license fee revenues and lower sales and royalty margins.

Cash and cash equivalents were $26.9 million as at March 31, 2010. This amount excludes an estimated $13.7 million of net proceeds received in connection with the registered direct offering completed on April 20, 2010.


Management will be hosting a conference call for the investment community beginning at 2:30 p.m. Eastern Time today, Thursday, May 13, 2010, to discuss first quarter 2010 results. Individuals interested in participating in the live conference call by telephone may dial in Canada, 514-807-9895 or 647-427-7450, outside Canada, 888-231-8191, or may listen through the Internet at A replay will be available on the Company's website for 30 days following the live event.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

Attachment: Financial summary

    Interim Consolidated Statements of Operations
    (in thousands, except share and per share data)
                                                             Three months
                                                            ended March 31,
                                                          2010          2009
                                                             $             $
    Sales and royalties                                  5,716         4,971
    License fees and other                                 706         1,140
                                                         6,422         6,111
    Operating expenses
    Cost of sales, excluding depreciation and
     amortization                                        4,617         3,694
    Research and development costs, net of tax
     credits and grants                                  5,701        11,437
    Selling, general and administrative expenses         2,792         3,554
    Depreciation and amortization
      Property, plant and equipment                        263           311
      Intangible assets                                    389           557
                                                        13,762        19,553
    Loss from operations                                (7,340)      (13,442)
    Other income
    Interest income                                         58           154
    Foreign exchange gain                                1,402           900
                                                         1,460         1,054
    Net loss for the period                             (5,880)      (12,388)
    Net loss per share
    Basic and diluted                                    (0.09)        (0.23)
    Weighted average number of shares
    Basic and diluted                               63,089,954    53,187,470

    Interim Consolidated Balance Sheet Information
    (in thousands)
                                                         As at         As at
                                                      March 31,  December 31,
                                                          2010          2009
                                                             $             $

    Cash and cash equivalents                           26,947        38,100
    Accounts receivable and other current assets        10,383        10,913
    Restricted cash                                        833           878
    Property, plant and equipment                        3,885         4,358
    Other long-term assets                              29,924        32,013
    Total assets                                        71,972        86,262

    Accounts payable and other current liabilities      14,777        19,211
    Current portion of long-term payable                    59            57
    Long-term payable                                      118           143
    Non-financial long-term liabilities*              53,848        57,625
    Total liabilities                                   68,802        77,036
    Shareholders' equity                                 3,170         9,226
    Total liabilities and shareholders' equity          71,972        86,262

    * Comprised mainly of deferred revenues and employee future benefits.

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Genetic testing for mutations ... the identification of more couples at risk of having ... presented today at the 2015 American Society of Human ... in Baltimore, Maryland . The study ... (NYSE: DGX ) are presenting at the conference ...
(Date:10/8/2015)... DURHAM, N.C. and WAYNE, Pa. ... leading management and technology consulting firm, has announced the ... Pennsylvania , majoring in a ... awarded over a two-year period. In addition, the selected ... industry through mentoring with Clarkston Consulting and participation in ...
(Date:10/8/2015)... BALTIMORE, Maryland , October 8, 2015 /PRNewswire/ ... .   --> Goldman ... specializing in the small cap and microcap sectors, ... sponsored research report on PharmaCyte Biotech, Inc. (OTCQB ... company focused on developing and preparing treatments for ...
(Date:10/8/2015)... , Oct. 8, 2015 The 2015 Nobel Prize ... University of Texas at Dallas. Aziz Sancar , who ... Dallas in 1977, is one of three scientists ... continuously monitor and repair damaged DNA on a molecular level.  ... and cell biology from UT Dallas in ...
Breaking Biology Technology:
... Future of Work World Congress , an energizing two-day ... development came together to envision the future workplace and develop ... Hill district and Independence Mall area of Philadelphia where the ... the restored and the new. This part of the city ...
... , a privately held IT firm, said it has acquired ... ,Berbee said it expects to keep all 16 employees of ... all. Strategies & Solutions provides hardware, software and services built ... ,Berbee has regional offices throughout the Midwest region, some of ...
... made a new version of its Mediasite presentation recorder for ... units to date and hopes to create a bigger market. ... show such as a PowerPoint deck with a video of ... a webcast. , ,According to company statements the Japanese market ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/26/2015)... 26th, 2015  Results of a TactioRPM pilot ... today at the Stanford Medicine X Conference. In ... Dashboards, Connected Health Devices and Pharmacogenomics", Roger ... will explain how senior patients equipped with connected ... pharmacist via the TactioRPM remote patient monitoring platform ...
Breaking Biology News(10 mins):
... New findings by Virginie Stevens ( CNRS ), Jean ... ) and colleagues show that interactions between dispersal and ... was published as open access paper in the journal ... plays a key role in gene flow among populations, ...
... decision making mechanisms in the human brain could mirror how ... have been found in decision making systems between humans and ... could teach us about how our brains work. Experts ... often paralysing thought process in humans, with scouts who seek ...
... solved the three-dimensional structure of a key region ... that control the activity of genes associated with ... understand the molecular mechanisms that regulate bacterial pathogenicity ... to conventional antibiotics. According to Jess Garca, research ...
Cached Biology News:
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: